Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: October 02, 2020
Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Journal: The Lancet. Infectious diseases
Published: May 21, 2018
CK-2127107 amplifies skeletal muscle response to nerve activation in humans.
Journal: Muscle & nerve
Published: May 25, 2017
A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: April 06, 2016
The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: February 22, 2016
Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study.
Journal: Pharmacology research & perspectives
Published: September 10, 2015
Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib.
Journal: Clinical pharmacology and therapeutics
Published: April 28, 2015
Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
Journal: The international journal of neuropsychopharmacology
Published: February 01, 2015
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
Journal: Journal of clinical pharmacology
Published: January 21, 2015
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Journal: Drug design, development and therapy
Published: January 02, 2015
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.
Journal: Clinical pharmacology and therapeutics
Published: October 16, 2014
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Journal: Basic & clinical pharmacology & toxicology
Published: July 28, 2014
Last Updated: 09/26/2026